Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

I.S. Nijhof; R.W.J. Groen; W.A. Noort; B. van Kessel; R. de Jong-Korlaar; J. Bakker; J.J.L. van Bueren; P.W.H.I. Parren; H.M. Lokhorst; N.W.C.J. van de Donk; A.C.M. Martens; T. Mutis

doi:https://doi.org/10.1158/1078-0432.CCR-14-1813

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

I.S. Nijhof, R.W.J. Groen, W.A. Noort, B. van Kessel, R. de Jong-Korlaar, J. Bakker, J.J.L. van Bueren, P.W.H.I. Parren, H.M. Lokhorst, N.W.C.J. van de Donk, A.C.M. Martens, T. Mutis

Research output: Contribution to journal › Article › Academic › peer-review

123 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	2802-2810
Journal	Clinical Cancer Research
Volume	21
Issue number	12
DOIs	https://doi.org/10.1158/1078-0432.CCR-14-1813
Publication status	Published - 2015

Access to Document

https://doi.org/10.1158/1078-0432.CCR-14-1813

Cite this

Nijhof, I. S., Groen, R. W. J., Noort, W. A., van Kessel, B., de Jong-Korlaar, R., Bakker, J., van Bueren, J. J. L., Parren, P. W. H. I., Lokhorst, H. M., van de Donk, N. W. C. J., Martens, A. C. M., & Mutis, T. (2015). Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clinical Cancer Research, 21(12), 2802-2810. https://doi.org/10.1158/1078-0432.CCR-14-1813

@article{da8d0bbffc0d431d9ca818535ef1a189,

title = "Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib",

author = "I.S. Nijhof and R.W.J. Groen and W.A. Noort and {van Kessel}, B. and {de Jong-Korlaar}, R. and J. Bakker and {van Bueren}, J.J.L. and P.W.H.I. Parren and H.M. Lokhorst and {van de Donk}, N.W.C.J. and A.C.M. Martens and T. Mutis",

year = "2015",

doi = "https://doi.org/10.1158/1078-0432.CCR-14-1813",

language = "Undefined/Unknown",

volume = "21",

pages = "2802--2810",

journal = "Clinical cancer research",

issn = "1078-0432",

publisher = "American Association for Cancer Research Inc.",

number = "12",

}

Nijhof, IS, Groen, RWJ, Noort, WA, van Kessel, B, de Jong-Korlaar, R, Bakker, J, van Bueren, JJL, Parren, PWHI, Lokhorst, HM, van de Donk, NWCJ, Martens, ACM & Mutis, T 2015, 'Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib', Clinical Cancer Research, vol. 21, no. 12, pp. 2802-2810. https://doi.org/10.1158/1078-0432.CCR-14-1813

TY - JOUR

T1 - Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

AU - Nijhof, I.S.

AU - Groen, R.W.J.

AU - Noort, W.A.

AU - van Kessel, B.

AU - de Jong-Korlaar, R.

AU - Bakker, J.

AU - van Bueren, J.J.L.

AU - Parren, P.W.H.I.

AU - Lokhorst, H.M.

AU - van de Donk, N.W.C.J.

AU - Martens, A.C.M.

AU - Mutis, T.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.1158/1078-0432.CCR-14-1813

DO - https://doi.org/10.1158/1078-0432.CCR-14-1813

M3 - Article

C2 - 25398450

SN - 1078-0432

VL - 21

SP - 2802

EP - 2810

JO - Clinical cancer research

JF - Clinical cancer research

IS - 12

ER -